Epistem Holdings Plc, the biotechnology and personalised medicine company, announced an agreement to raise £2.8 million via a placing at 350p per share in exchange for shares representing 9.1% of the enlarged share capital. The funds will be used to accelerate the development and commercialisation of Genedrive.
The EHP share price has decreased by 10% over the last year.
Epistem Holdings Plc is currently graded b by LCF Research. To learn more, follow the link.
Disclaimer:
This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.
Epistem Holdings Plc is a holding company. The Company is engaged in provision of services to the biotechnology and pharmaceutical industries, covering pre-clinical testing and gene biomarker and diagnostic services and the development of novel therapeutics for partner companies. The trading activity of the Company is principally undertaken in the subsidiary undertaking, Epistem Limited. The Company operates in three segments: Contract Research Services, Personalized Medicine and Novel Therapies. Contract Research Services provides pre-clinical testing services. Personalized Medicine specializes in molecular measures of biological effect and point of care molecular diagnostic testing. Novel Therapies is discovering key regulators of epithelial stem cells. more »
